Avalon GloboCare Corp. (AVCO): Price and Financial Metrics


Avalon GloboCare Corp. (AVCO): $0.69

0.01 (+1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AVCO Stock Summary

  • With a market capitalization of $61,920,668, Avalon GloboCare Corp has a greater market value than only 10.77% of US stocks.
  • AVCO's went public 3.4 years ago, making it older than merely 10.82% of listed US stocks we're tracking.
  • With a price/sales ratio of 40.97, Avalon GloboCare Corp has a higher such ratio than 95.62% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Avalon GloboCare Corp, a group of peers worth examining would be LGHL, EMX, GP, SAND, and GBOX.
  • AVCO's SEC filings can be seen here. And to visit Avalon GloboCare Corp's official web site, go to www.avalon-globocare.com.

AVCO Valuation Summary

  • In comparison to the median Healthcare stock, AVCO's price/sales ratio is 1647.37% higher, now standing at 66.4.
  • Over the past 34 months, AVCO's price/earnings ratio has gone up 30.4.
  • AVCO's EV/EBIT ratio has moved up 32.2 over the prior 34 months.

Below are key valuation metrics over time for AVCO.

Stock Date P/S P/B P/E EV/EBIT
AVCO 2021-08-31 66.4 27.8 -8.1 -8.5
AVCO 2021-08-30 66.4 27.8 -8.1 -8.5
AVCO 2021-08-27 69.0 28.8 -8.4 -8.8
AVCO 2021-08-26 67.7 28.3 -8.2 -8.7
AVCO 2021-08-25 69.0 28.8 -8.4 -8.8
AVCO 2021-08-24 64.5 27.0 -7.9 -8.3

AVCO Stock Price Chart Interactive Chart >

Price chart for AVCO

AVCO Price/Volume Stats

Current price $0.69 52-week high $1.15
Prev. close $0.68 52-week low $0.40
Day low $0.68 Volume 79,000
Day high $0.72 Avg. volume 129,035
50-day MA $0.52 Dividend yield N/A
200-day MA $0.71 Market Cap 68.86M

Avalon GloboCare Corp. (AVCO) Company Bio


Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.


AVCO Latest News Stream


Event/Time News Detail
Loading, please wait...

AVCO Latest Social Stream


Loading social stream, please wait...

View Full AVCO Social Stream

Latest AVCO News From Around the Web

Below are the latest news stories about Avalon GloboCare Corp that investors may wish to consider to help them evaluate AVCO as an investment opportunity.

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ: AVCO ) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies . Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for … Full story available on Benzinga.com

Benzinga | February 14, 2022

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeuticsClinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areasAppoints Dongfang Liu, Ph.D., a world-class scientist and expert in CAR-NK technology, to Avalon’s Scientific and Clinical Advisory Board FREEHOLD, N.J., Feb. 14, 2

Yahoo | February 14, 2022

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update. “We believe we have made significant p

Yahoo | January 4, 2022

Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market

Avalon’s Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the businessFREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0 million of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s com

Yahoo | December 22, 2021

Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development

Avalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design “QTY Code” technology with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2, to accurately predict the 3D structures of protein receptors that have potential use as cellular therapy targetsA study of the application and capabilities of the dual technology was published in the November 2021 issue of Life, a peer-reviewed life sciences journal FREEHOLD, N.J., Dec. 09, 2021 (GLOB

Yahoo | December 9, 2021

Read More 'AVCO' Stories Here

AVCO Price Returns

1-mo 50.00%
3-mo 54.29%
6-mo -17.86%
1-year -38.39%
3-year -64.06%
5-year -48.89%
YTD -15.85%
2021 -26.79%
2020 -41.97%
2019 -29.82%
2018 10.00%
2017 N/A

Continue Researching AVCO

Want to see what other sources are saying about Avalon GloboCare Corp's financials and stock price? Try the links below:

Avalon GloboCare Corp (AVCO) Stock Price | Nasdaq
Avalon GloboCare Corp (AVCO) Stock Quote, History and News - Yahoo Finance
Avalon GloboCare Corp (AVCO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0102 seconds.